Effective electrophoretic mobilities and charges of anti-VEGF proteins determined by capillary zone electrophoresis.
Macromolecules such as therapeutic proteins currently serve an important role in the treatment of eye diseases such as wet age-related macular degeneration and diabetic retinopathy. Particularly, bevacizumab and ranibizumab have been shown to be effective in the treatment of these diseases. Iontophoresis can be employed to enhance ocular delivery of these macromolecules, but the lack of information on the properties of these macromolecules has hindered its development. The objectives of the present study were to determine the effective electrophoretic mobilities and charges of bevacizumab, ranibizumab, and model compound polystyrene sulfonate (PSS) using capillary zone electrophoresis. Salicylate, lidocaine, and bovine serum albumin (BSA), which have known electrophoretic mobilities in the literature, were also studied to validate the present technique. The hydrodynamic radii and diffusion coefficients of BSA, bevacizumab, ranibizumab, and PSS were measured by dynamic light scattering. The effective charges were calculated using the Einstein relation between diffusion coefficient and electrophoretic mobility and the Henry equation. The results show that bevacizumab and ranibizumab have low electrophoretic mobilities and are net negatively charged in phosphate buffered saline (PBS) of pH 7.4 and 0.16M ionic strength. PSS has high negative charge but the electrophoretic mobility in PBS is lower than that expected from the polymer structure. The present study demonstrated that capillary electrophoresis could be used to characterize the mobility and charge properties of drug candidates in the development of iontophoretic drug delivery.
Division of Pharmaceutical Sciences, College of Pharmacy, University of Cincinnati, 3225 Eden Ave, 136 HPB, Cincinnati, OH 45267, United States. kevin.li@uc.edu
S Kevin
SK
Li
Mark R
MR
Liddell
He
H
Wen
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002021:Buffers; D016503:Drug Delivery Systems; D019075:Electrophoresis, Capillary; D006801:Humans; D057446:Hydrodynamics; D006863:Hydrogen-Ion Concentration; D007478:Iontophoresis; D008268:Macular Degeneration / Q000188:drug therapy / Q000378:metabolism; D008956:Models, Chemical; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D002021:Buffers; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
Exp Eye Res. 2004 Mar;78(3):751-7
15106955
J Pharm Sci. 2010 Mar;99(3):1152-68
19705420
J Chromatogr A. 2003 May 23;998(1-2):1-20
12862367
J Pharm Biomed Anal. 2003 Oct 15;33(3):379-91
14550857
Oncogene. 2003 Dec 8;22(56):9097-106
14663488
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1785-90
9050856
Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):281-305
11259844
J Pharm Sci. 2005 Dec;94(12):2667-75
16258982
J Pharm Sci. 1997 Jun;86(6):680-9
9188050
J Pharm Sci. 1996 Jul;85(7):781-8
8819006
Toxicol Pathol. 1999 Sep-Oct;27(5):536-44
10528633
Adv Funct Mater. 2010 Sep 8;20(23):4168-4174
21274422
J Ocul Pharmacol Ther. 2003 Apr;19(2):145-51
12804059
J Control Release. 2006 Feb 21;110(3):479-89
16343678
Ophthalmology. 2005 Jun;112(6):1035-47
15936441
J Chromatogr A. 1999 Oct 1;857(1-2):263-73
10536845
Clin Chem Lab Med. 2003 Jun;41(6):720-3
12880134
Br J Ophthalmol. 2010 Feb;94(2):170-3
20139290
Nat Biotechnol. 2005 Sep;23(9):1137-46
16151407
Int J Pharm. 2010 Mar 30;388(1-2):107-13
20045044
J Pharm Sci. 2001 Jul;90(7):915-31
11458339
Electrophoresis. 2000 Nov;21(17):3529-40
11271468
J Pharm Pharmacol. 2010 Sep;62(9):1189-94
20796199
J Control Release. 2007 Sep 26;122(2):165-72
17707106
Vision Res. 2010 Mar 31;50(7):680-5
19854210
Adv Drug Deliv Rev. 2004 Mar 27;56(5):619-58
15019750
Anal Chem. 1998 Apr 15;70(8):1581-4
9569767
Exp Eye Res. 2002 Jan;74(1):51-9
11878818
Electrophoresis. 2003 Dec;24(22-23):4116-27
14661238
Analyst. 2006 Sep;131(9):1034-43
17047804
J Immunol Methods. 1992 Oct 19;155(1):1-17
1383343
Electrophoresis. 2006 Jun;27(12):2263-82
16786477
J Chromatogr A. 2002 Dec 6;979(1-2):369-77
12498268
Anal Chim Acta. 2008 Jan 7;606(1):98-107
18068776